Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3109)
All Articles published online
|
Jun 21, 2008 (publication date) through Nov 3, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Pearlman BL. Extended-therapy duration for chronic hepatitis C, genotype 1: The long and the short of it. World J Gastroenterol 2008; 14(23): 3621-3627 [PMID: 18595128 DOI: 10.3748/wjg.14.3621] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i23/3621.htm |
| Number | Citing Articles |
| 1 |
Ian K. Mangion, Cheng-yi Chen, Hongmei Li, Peter Maligres, Yonggang Chen, Melodie Christensen, Ryan Cohen, Ingyu Jeon, Artis Klapars, Shane Krska, Hoa Nguyen, Robert A. Reamer, Benjamin D. Sherry, Ilia Zavialov. Enantioselective Synthesis of an HCV NS5a Antagonist. Organic Letters 2014; 16(9): 2310 doi: 10.1021/ol500971c
|
| 2 |
Jeffrey L. Romine, Denis R. St. Laurent, John E. Leet, Scott W. Martin, Michael H. Serrano-Wu, Fukang Yang, Min Gao, Donald R O’Boyle, Julie A. Lemm, Jin-Hua Sun, Peter T. Nower, Xiaohua (Stella) Huang, Milind S. Deshpande, Nicholas A. Meanwell, Lawrence B. Snyder. Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes. ACS Medicinal Chemistry Letters 2011; 2(3): 224 doi: 10.1021/ml1002647
|
| 3 |
José M. Ladero. Optimizing dosage and duration therapy for chronic hepatitis C «difficult-to-treat patients». Annals of Hepatology 2008; 7(4): 392 doi: 10.1016/S1665-2681(19)31846-0
|
| 4 |
Xi Zong, Jin Cai, Junqing Chen, Peng Wang, Gaoxin Zhou, Bo Chen, Wei Li, Min Ji. Design and synthesis of imidazole N–H substituted amide prodrugs as inhibitors of hepatitis C virus replication. Bioorganic & Medicinal Chemistry Letters 2015; 25(16): 3147 doi: 10.1016/j.bmcl.2015.06.006
|
| 5 |
Min Gao, Richard E. Nettles, Makonen Belema, Lawrence B. Snyder, Van N. Nguyen, Robert A. Fridell, Michael H. Serrano-Wu, David R. Langley, Jin-Hua Sun, Donald R. O’Boyle II, Julie A. Lemm, Chunfu Wang, Jay O. Knipe, Caly Chien, Richard J. Colonno, Dennis M. Grasela, Nicholas A. Meanwell, Lawrence G. Hamann. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465(7294): 96 doi: 10.1038/nature08960
|
| 6 |
Seyed Moayed Alavian, Seyed Vahid Tabatabaei, Bita Behnava, Nastaran Mahboobi. Optimal Duration of Treatment for HCV Genotype 1 Infection in Slow Responders: A Meta-Analysis. Hepatitis Monthly 2011; 11(8): 612 doi: 10.5812/kowsar.1735143X.2187
|
| 7 |
Phil McEwan, Ray Kim, Yong Yuan. Assessing the Cost Utility of Response-Guided Therapy in Patients with Chronic Hepatitis C Genotype 1 in the UK Using the MONARCH Model. Applied Health Economics and Health Policy 2013; 11(1): 53 doi: 10.1007/s40258-012-0002-0
|
| 8 |
Paul M. Scola, Alan Xiangdong Wang, Andrew C. Good, Li-Qiang Sun, Keith D. Combrink, Jeffrey A. Campbell, Jie Chen, Yong Tu, Ny Sin, Brian L. Venables, Sing-Yuen Sit, Yan Chen, Anthony Cocuzza, Donna M. Bilder, Stanley D’Andrea, Barbara Zheng, Piyasena Hewawasam, Min Ding, Jan Thuring, Jianqing Li, Dennis Hernandez, Fei Yu, Paul Falk, Guangzhi Zhai, Amy K. Sheaffer, Chaoqun Chen, Min S. Lee, Diana Barry, Jay O. Knipe, Wenying Li, Yong-Hae Han, Susan Jenkins, Christoph Gesenberg, Qi Gao, Michael W. Sinz, Kenneth S. Santone, Tatyana Zvyaga, Ramkumar Rajamani, Herbert E. Klei, Richard J. Colonno, Dennis M. Grasela, Eric Hughes, Caly Chien, Stephen Adams, Paul C. Levesque, Danshi Li, Jialong Zhu, Nicholas A. Meanwell, Fiona McPhee. Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection. Journal of Medicinal Chemistry 2014; 57(5): 1708 doi: 10.1021/jm401840s
|
| 9 |
Masoud Keikha, Majid Eslami, Bahman Yousefi, Mohammad Ali-Hassanzadeh, Ali Kamali, Masoud Yousefi, Mohsen Karbalaei. HCV genotypes and their determinative role in hepatitis C treatment. VirusDisease 2020; 31(3): 235 doi: 10.1007/s13337-020-00592-0
|
| 10 |
Nipaporn Pichetshote, Erik Groessl, Helen Yee, Samuel B. Ho. Optimizing the Dose and Duration of Therapy for ChronicHepatitis C. Gut and Liver 2009; 3(1): 1 doi: 10.5009/gnl.2009.3.1.1
|
| 11 |
Lienda Bashier Eltayeb, Deema I Fallatah, Altaf Ali Mangi. Genomic divergence of Hepatitis C virus towards common prescribed interferon regimens on sustained virologic response (SVR) . Journal Of Advanced Pharmacy Education And Research 2022; 12(3): 59 doi: 10.51847/EJ82rOFBiq
|